Biomea Fusion is a biopharmaceutical company that develops covalent small molecule drugs to treat genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a potent and selective covalent inhibitor of menin. The company was founded in 2017 and is based in Redwood City, California.